TORONTO, ONTARIO--(Marketwired - Feb. 6, 2017) - Abattis Bioceuticals Corp. is in default of CSE requirements. Effective immediately, Abattis Bioceuticals will be suspended pursuant to CSE Policy 3. The suspension is considered a Regulatory Halt as defined in National Instrument 23-101 Trading Rules. A cease trade order has been issued by the British Columbia Securities Commission and the Ontario Securities Commission.

Date: Effective immediately, February 6, 2017

Symbol: ATT